Celecoxib upregulates multidrug resistance proteins in colon cancer: Lack of synergy with standard chemotherapy

Current Cancer Drug Targets

Volumn 8, Issue 5, 2008, Pages 414-420

  Gradilone, A ^a   Pulcinelli, F M ^a   Lotti, L V ^a   Trifiro E ^a   Martino, S ^a   Gandini, O ^a   Gianni, W ^b   Frati, L ^a   Agliano A M ^a   Gazzaniga, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b INRCA   (Italy)

Author keywords

Celecoxib; Colorectal cancer; MRP4; MRP5; Multidrug resistance

Indexed keywords

ABC TRANSPORTER; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; CELECOXIB; CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; OXALIPLATIN; TOPOTECAN;

ANTIBODY LABELING; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL MEMBRANE; CELL VIABILITY; CELLULAR DISTRIBUTION; COLON CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG TRANSPORT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOELECTRON MICROSCOPY; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL MEMBRANE; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLOOXYGENASE INHIBITORS; CYTOPLASM; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOENZYME TECHNIQUES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEINS; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUBCELLULAR FRACTIONS; SULFONAMIDES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 48849102542     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908785133178     Document Type: Article

References (17)

1. Stein, U.; Schlag, P. M. Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res. 2007, 176, 61-80.
2. Eisinger, A. L.; Prescott, S. M.; Jones, D. A.; Stafforini, D. M. The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat. 2007, 82(1-4), 147-154.
3. Sinicrope, F. A.; Gill, S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev. 2004, 23(1-2), 63-75.
4. Phillips, R. K.; Wallace, M. H.; Lynch, P. M.; Hawk, E.; Gordon, G. B.; Saunders, B. P.; Wakabayashi, N.; Shen, Y.; Zimmerman, S.; Godio, L.; Rodrigues-Bigas, M.; Su, L. K.; Sherman, J.; Kelloff, G.; Levin, B.; Steinbach, G. FAP Study Group. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002, 50(6), 857-860.
5. Chu, A. J.; Chou, T. H.; Chen, B. D. Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. Front. Biosci. 2004, 9, 2697-2713.
6. Andre, T.; Tournigand, C.; Mineur, L.; Fellague-Chebra, R.; Flesch, M.; Mabro, M.; Hebbar, M.; Postel Vinay, S.; Bidard, F. C.; Louvet, C.; de Gramont, A. GERCOR (French Oncology Research Group). Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann. Oncol. 2007, 18(1), 77-81.
7. Maiello, E.; Giuliani, F.; Gebbia, V.; Di Renzo, N.; Pezzella, G.; Romito, S.; Mallamaci, R.; Lopez, M.; Colucci, G. FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann. Oncol. 2006, (suppl 7), vii55-vii59.
8. El-Rayes, B. F.; Zalupski, M. M.; Manza, S. G.; Rusin, B.; Ferris, A.M.; Vaishampayan, U.; Heilbrun, L. K.; Venkatramanamoorthy, R.; Shields, A. F.; Philip, P. A. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemother. Pharmacol. 2008, 61, 283-289.
9. Lim, Y.; Rhee, J. C.; Bae, Y. M.; Chun, W. J. Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. World J. Gastroenterol. 2007, 13(13), 1947-1952.
10. Gradilone, A.; Pulcinelli, F. M.; Lotti, L. V.; Martino, S.; Mattiello, T.; Frati, L.; Aglianò, A. M.; Gazzaniga, P. Celecoxib induces MRP-4 in lung cancer cells: therapeutic implications. J. Clin. Oncol. 2007, 25(27), 4318-4320.
11. Norris, M. D.; Smith, J.; Tanabe, K.; Tobin, P.; Flemming, C.; Scheffer, G. L.; Wielinga, P.; Cohn, S. L.; London, W. B.; Marshall, G. M.; Allen, J. D.; Haber, M. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol. Cancer Ther. 2005, 4(4), 547-553.
12. Cascorbi, I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 2006, 112(2), 457-473.
13. Gradilone, A.; Silvestri, I.; Scarpa, S.; Morrone, S.; Gandini, O.; Pulcinelli, F. M.; Gianni, W.; Frati, L.; Aglianò, A. M.; Gazzaniga, P. Failure of apoptosis and activation of NFkB by celecoxib and aspirin in lung cancer cell lines. Oncol. Rep. 2007, 17, 823-828.
14. Inoue, Y.; Tanaka, K.; Hiro, J.; Yoshiyama, S.; Toiyama, Y.; Eguchi, T.; Miki, C.; Kusunoki, M. In vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer. Int. J. Oncol. 2006, 2, 479-486.
15. Allegra, C.; Blanke, C.; Buyse, M.; Goldberg, R.; Grothey, A.; Meropol, N. J.; Saltz, L.; Venook, A.; Yothers, G.; Sargent, D. End points in advanced colon cancer clinical trials: a review and proposal. J. Clin. Oncol. 2007, 25(24), 3572-3575.
16. Huls, G.; Koornstra, J. J.; Kleibeuker, J. H. Non-steroidal antiinflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 2003, 362(9379), 230-232.
17. Wildy, K. S.; Wasko, M. C. Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis. Hand Clin. 2001, 17(2), 321-338.